Knott David M buys $2,057,778 stake in ACADIA Pharmaceuticals (ACAD)

ACADIA Pharmaceuticals (ACAD) : Knott David M scooped up 60,097 additional shares in ACADIA Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 65,597 shares of ACADIA Pharmaceuticals which is valued at $2,057,778.ACADIA Pharmaceuticals makes up approximately 0.47% of Knott David M’s portfolio.

Other Hedge Funds, Including , Marshall Wace Llp sold out all of its stake in ACAD during the most recent quarter. The investment firm sold 37,174 shares of ACAD which is valued $1,166,148.Rhumbline Advisers boosted its stake in ACAD in the latest quarter, The investment management firm added 18,190 additional shares and now holds a total of 99,030 shares of ACADIA Pharmaceuticals which is valued at $3,106,571. ACADIA Pharmaceuticals makes up approx 0.01% of Rhumbline Advisers’s portfolio. Global X Management Co added ACAD to its portfolio by purchasing 244 company shares during the most recent quarter which is valued at $7,776.First Midwest Bank Trust Division boosted its stake in ACAD in the latest quarter, The investment management firm added 10,124 additional shares and now holds a total of 40,344 shares of ACADIA Pharmaceuticals which is valued at $1,510,479. ACADIA Pharmaceuticals makes up approx 0.18% of First Midwest Bank Trust Division’s portfolio.

ACADIA Pharmaceuticals closed down -0.24 points or -0.73% at $32.62 with 14,85,046 shares getting traded on Monday. Post opening the session at $32.86, the shares hit an intraday low of $32.14 and an intraday high of $32.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, ACADIA Pharmaceuticals reported $-0.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.16 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.47. The company had revenue of $.97 million for the quarter, compared to analysts expectations of $.71 million. The company’s revenue was up 96900.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.39 EPS.

Many Wall Street Analysts have commented on ACADIA Pharmaceuticals. ACADIA Pharmaceuticals was Downgraded by BofA/Merrill to ” Neutral” on Jun 22, 2016.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis Alzheimer’s disease psychosis Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan has discovered and engaged in the development of small-molecule product candidates such as alpha adrenergic agonists and muscarinic receptors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *